Cantor Fitzgerald reiterated its Buy rating on Synergy Pharmaceuticals (NASDAQ: SGYP) and increased its price target from $7 to $13. Cantor Fitzgerald commented, "Positive data announcement is a key catalyst: Synergy announced positive top-line results from its Phase IIb/III chronic constipation (CC) trial of plecanatide.